Navigation Links
AutoImmune Inc. Files Certificate of Dissolution and Completes Sale of Colloral® Business; Trading of Common Stock to Cease After June 30, 2010
Date:6/30/2010

PASADENA, Calif., June 30 /PRNewswire-FirstCall/ -- AutoImmune Inc. (Pink Sheets: AIMM) today announced that it filed its Certificate of Dissolution with the Delaware Secretary of State on June 30, 2010 (the "Final Record Date"), in accordance with its previously announced Plan of Complete Liquidation and Dissolution. As a result of such filing, the company has closed its stock transfer books and will discontinue recording transfers of its common stock, except by will, intestate succession or operation of law effective at the close of business on the Final Record Date.  All liquidating distributions from AutoImmune after the Final Record Date will be made to stockholders of record on the Final Record Date pro rata according to their holdings of common stock as of the Final Record Date.

In furtherance of the company's Plan of Complete Liquidation and Dissolution, the company has completed a sale of the assets of the Colloral® business, the company's joint venture with Deseret Laboratories, Inc.  As part of the sale transaction and dissolution process, Colloral LLC was merged with and into AutoImmune.

As previously announced, AutoImmune's business activities are now limited to those necessary to preserve the value of its assets, wind up its business and affairs, and distribute its assets in accordance with the Plan of Complete Liquidation and Dissolution.

About AutoImmune Inc.

AutoImmune is a biopharmaceutical company that has focused on the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

website:

SOURCE AutoImmune Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
2. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
3. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
4. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
5. Lilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies
6. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
9. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Valeritas, Inc., ... designed for patients with Type 2 diabetes, announced today ... Chain Excellence Award. The award was presented October 16 ... Columbus, Ohio . ... judged across a variety of metrics specifically targeted at ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, ... leader in bioactive lipid-targeted therapeutics, received official notification from ... been granted another key patent supporting its iSONEP™ ... issued patent, European patent No. 2087002, claims compositions ... in Lpath,s two lead compounds, iSONEP and ASONEP. ...
(Date:10/20/2014)... YORK and RALEIGH, N.C., Oct. 20, 2014 ... Hereditary Neuropathy Foundation (HNF), both philanthropies, announced today ... drug candidates for the treatment of the rare ... BioPontis Alliance announced its alliance model earlier ... a first demonstration of a collaborative model where ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... 5, 2012  Orexigen ® Therapeutics, Inc. (Nasdaq: ... presenting at the 30th Annual J.P. Morgan Healthcare Conference in ... at 9:00 a.m. PST (12:00 p.m. EST). To listen to ... visit the Investor Relations section of the Company,s Web site ...
... , Company expects to meet or exceed ... and earnings declines due to Zyprexa patent expiration. , ... , Company expects to keep 2012 operating expenses essentially flat ... be in the range of $3.10 - $3.20. , ...
Cached Medicine Technology:Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 2Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 3Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 4Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 5
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... N.C. , Jan. 19 Sodium consumption is a hot ... their recipes to find ways to have products that everyone can feel ... in sodium—40% to 70% less than table salt—and tastes good. , In ... salt. Total sales that year did not even reach $100.00 . ...
... , , ATLANTA , Jan. ... Director of the Unit of Interventional Radiology at the European ... Oncology 2010 Best Poster Award by Dr. Shaun Samuels ... Micro-Bland Embolization Combined with Radiofrequency Ablation for Treating Complex Hepatic ...
... Speaker Nancy Pelosi , House Majority Leader Steny ... availability this afternoon in the Capitol following a Democratic leadership meeting. Below ... , As you may be aware, we just had a meeting ... you,re aware of in Massachusetts and the rest, we,re still ...
... rationing health care, particularly at the end of life, may ... Johns Hopkins emeritus professor of neurology called for the start ... this month,s issue of the Journal of Medical Ethics ... Professor Emeritus of Pediatric Neurology and a faculty member of ...
... with spinal injuries, experts say , , TUESDAY, Jan. 19 ... were able to form proper brain connections in newborn mice, ... their study was the first to show that stem cells ... link correctly in the brain. The findings, they say, could ...
... The cholesterol drugs might reduce risk of infection, researchers find ... known as statins hold promise as a treatment for sickle ... , The findings, published Jan. 19 in the ... mice, so it,s not clear if humans with the disease ...
Cached Medicine News:Health News:Ocean's Flavor Natural Sea Salt is Helping Companies Reach Low Sodium Goals 2Health News:Ocean's Flavor Natural Sea Salt is Helping Companies Reach Low Sodium Goals 3Health News:Orsi Awarded First Place for Procedure with Embozene(TM) Microspheres 2Health News:Transcript of Pelosi, House Democratic Leaders' Press Availability Today Following Leadership Meeting 2Health News:Transcript of Pelosi, House Democratic Leaders' Press Availability Today Following Leadership Meeting 3Health News:Reasoning through the rationing of end-of-life care 2Health News:Stem Cells Become Functioning Neurons in Mice 2